leisure time -WSS

leisure time

author：leisure time 2025-10-01 10:58:35 - browse：32318

Adam's take main illustration — Molly Ferguson/STAT

Thoughts about Cytokinetics after Wednesday night’s financing announcement:

1. Management is raising $500 million at $51 per share, when the stock was at $45 per share before the aficamtem study readout in December. That’s shocking. Somehow, management has not only removed all the M&A premium from the stock, but much or most of aficamtem’s value, too.

2. Omecamtiv’s resurrection: Are you kidding me? No one thinks bringing back this heart failure drug is a good idea, except management. Making it worse, the terms of the Royalty Pharma loan are, again, shocking. All the risk is borne by Cytokinetics. Royalty, in fact, may do better if omecamtiv fails.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Alkermes shareholders re
Next article： Medicare bonuses could stop drug shortages under Senate plan

WSS

Printout prescription drug information shouldn’t go digital

Chimpanzees, like humans and whales, get menopause: Study

Testing for cancer recurrence creates a new limbo for patients

FDA has safety concerns on CRISPR

FDA has safety concerns on CRISPR

Readout Newsletter: New research from Sanofi, Regeneron, etc.

focus

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

focus

New air purifier tech could be key to improving indoor air quality

Traditional Chinese medicine benefits explored in new JAMA study

Alkermes shareholders re

Inaction leaves children at risk from dangerous chemotherapy drug

Medicare details structure of new drug price negotiation program

Prior authorization reform is both possible and imperative

How one medical school became remarkably diverse

Head of FDA's diagnostics center, who led through Covid, retires

At least 13 dead in Texas as scorching temps continue

To bolster infectious disease surveillance, genomics powerhouses team up

hotspot

Hospitals warn Medicare's drug payment fix is ‘unlawful’

Senate panel to vote on hospitals, PBMs, prisoner care

Maker of FluMist seeks to allow at

Pumping milk in bathrooms at health conferences is common

Why Sanofi got shellacked over its spinoff

Medicare drug price lawsuits could be good politics for Biden

hotspot

Wikipedia

focus

leisure time